Qualification of Gene and Protein Signatures from CITE-seq Data for Deep Immunophenotyping in Human Clinical Trials

Home > Science Hub > Qualification of Gene and Protein Signatures from CITE-seq Data for Deep Immunophenotyping in Human Clinical Trials
Back to the list

April 7, 2025

Matt Clutter

You might also be interested by

Posters

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

More info

Posters

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

March 3, 2026

More info

Posters

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

March 3, 2026

More info

Web News

CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI

March 3, 2026

More info